Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utomilumab, Cetuximab, and Irinotecan in Advanced Colorectal Cancer
NCT03290937Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2017
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of utomilumab in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Recommended Phase 2 Dose up to 4 years and Objective Response Rate up to 4 years. Started Dec 2017; status: completed.
02
Drugs
utomilumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03290937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290937.